A breakthrough treatment option for blood cancers, solid tumors and autoimmune disorders.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
CAR-T cell therapy is transforming modern medicine by using a patient’s own immune system to fight cancer. The first breakthrough came in 2012, when 6-year-old Emily Whitehead, with relapsed leukemia and no options left, became the first child to receive CAR-T cell therapy. She went into remission and remains cancer-free today—an inspiring story that proved what’s possible.
Unlike chemotherapy or radiation, CAR-T reprograms T cells to recognize and destroy cancer, with lasting protection. It is now approved for several blood cancers, including leukemia, lymphoma, and multiple myeloma. Research is rapidly expanding into solid tumors—such as gastric cancer and gastroesophageal junction (GEJ) cancer—as well as autoimmune diseases.
The U.S. pioneered the first approvals, but today China is leading in clinical trials, expanding access, and driving innovation. At cartcellschina.com, we provide knowledge and help international patients explore CAR-T treatment options in China.
CAR T-cell therapy, or Chimeric Antigen Receptor T-cell therapy, is an advanced form of immunotherapy used to treat certain types of cancer.
It involves modifying a patient’s own T-cells, a type of white blood cell essential for immune response, to better recognize and attack cancer cells.
This innovative therapy has shown significant success in treating hematologic malignancies, such as certain types of leukemia, lymphoma and multiple myeloma, it represents a groundbreaking approach in personalized cancer treatment, offering new hope for patients with otherwise difficult-to-treat cancers.
To understand how CAR T-cell therapy works, it’s essential to know T cells, which are white blood cells in your immune system. Your immune system monitors for intruders, including cancer, by tracking proteins called antigens on abnormal cells.
T cells have receptors on their surface that recognize these abnormal antigens. When a T cell’s receptor identifies a suspicious cell, it becomes activated, destroys the abnormal cell, and triggers other immune responses to aid in the attack.
However, T-cell receptors don’t always detect cancer cells. This is where CAR T cells come in. Scientists modify your T cells by adding a lab-made gene for a chimeric antigen receptor, allowing them to recognize specific cancer cell antigens. These modified CAR T cells are then grown in sufficient numbers to effectively target cancer cells.
Once infused back into your bloodstream, CAR T cells detect and destroy cancerous cells while continuing to multiply, providing a long-lasting supply of targeted cells. This enduring nature is why CAR T-cell therapy is referred to as a “living drug.”
CAR T cell therapy is a scientifically advanced approach for cancer treatment, it is highly effective in the treatment of blood cancers, offering hope to those whose cancer returned after other treatments. People with the following conditions are candidates to consider CAR T-cell therapy at our medical centers.
The regulatory processes in China have aimed to ensure that these therapies meet high standards before being made available to patients, contributing to advancements in cancer treatment both domestically and globally.
CAR T-cell therapies developed in China have undergone rigorous clinical trials, demonstrating safety and efficacy. These therapies have gained approval based on comprehensive data that supports their effectiveness in treating various hematologic malignancies.
Studies have demonstrated that more than 85% of patients had complete remission right after CAR T-cell treatment and 65% of them remained free of cancer 12 months later.
CAR T-cell therapy specifically targets antigens on myeloma cells, such as BCMA (B-cell maturation antigen). This precision helps to effectively eliminate cancer cells while sparing healthy cells, reducing collateral damage.
CAR T-cell therapy uses the patient’s own T-cells, which are genetically modified to recognize and attack cancer cells, offering a tailored approach to each individual’s disease.
CAR T-cell therapy has shown significant effectiveness, leading to deep and durable remissions in many patients, particularly those who have relapsed or become refractory to other treatments.
Many patients experience deep and lasting remissions after CAR T-cell therapy, even those who have relapsed or become refractory to conventional treatments. This potential for long-term disease control is a significant benefit.
Successful treatment can lead to a better quality of life post-therapy, as patients may experience fewer side effects than with conventional treatments.
Unlike some conventional therapies that may take months, CAR T-cell treatment can often be administered within a shorter time frame after T-cell collection and modification.
There are six CAR T-cell therapies with China National Medical Products Administration (NMPA) approval to treat specific type of blood cancers. These therapies are either developed through collaborations between Chinese and Western biopharmaceutical companies or created independently by Chinese firms. These therapies are:
Yescarta for large B-cell lymphoma (LBCL)
Yescarta is an FDA-approved CAR T-cell therapy that has been granted in China since 2021 for the treatment of large B-cell lymphoma.
Carteyva for large B-cell lymphoma (LBCL), follicular lymphoma (FL) or mantle cell lymphoma (MCL)
A CAR T-cell therapy developed based on the cell processing platform of Breyanzi, an FDA-approved CAR T-cell therapy for lymphoma treatment.
CNCT19 for B-cell acute lymphoblastic leukemia (B-ALL)
This is the first CAR T-cell therapy for leukemia in China with independent intellectual property rights.
Fucaso for relapsed or refractory multiple myeloma (MM)
Fucaso is the first fully-human BCMA CAR T-cell therapy for r/r multiple myeloma in the world, it is devloped by IASO Bio and Innovent.
Zevor-cel for relapsed or refractory multiple myeloma (MM)
A fully-human BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma.
Carvykti for relapsed or refractory multiple myeloma (MM)
A US FDA approved CAR T-cell therapy is now available in China.
CAR-T therapy is not just another cancer treatment—it is a living medicine. By turning a patient’s immune system into a precise, long-lasting weapon against cancer, CAR-T offers hope where chemotherapy and other treatments may no longer work.
Feature | CAR-T Therapy | Chemotherapy | Radiation / Other Standard Therapies |
|---|---|---|---|
Targeting | Highly specific—targets cancer cells via engineered receptors | Non-specific—damages both cancerous and healthy cells | Localized (radiation) or systemic, not patient-specific |
Personalization | Tailored to each patient’s own immune cells | Standardized drug protocols | Generalized treatment, not individualized |
Mechanism | Uses living T cells to attack and remember cancer | Uses chemical agents to kill rapidly dividing cells | Uses radiation beams or surgery to remove/destroy tumors |
Durability | Can persist in the body for years, offering long-term remission | Effects stop when treatment ends | Local effect, recurrence possible |
Side Effects | Immune-related (e.g., cytokine release syndrome), often manageable in specialized centers | Hair loss, nausea, low immunity, organ toxicity | Local effect, recurrence possible |
Patient Assessment
Leukapheresis
Bridging Therapy
Lymphodepletation
CAR-T Infusion
Long-term Follow-up
In order to maximize CAR T-cell therapy’s efficacy, a list of medical exams, analysis, pre-treatment, and post-treatment observations are also important in cancer treatment with CAR-T therapy. Also, the technologies used in the treatment and location of the manufacturing facilities are factors that may affect the time frame of CAR T-cell therapy, the average time frame is about 6-12 weeks.
China has become a global leader in cell-based therapies, particularly CAR T-cell therapy for cancer. The country has made remarkable progress in both research and clinical application, offering cutting-edge treatments that are reshaping cancer care.
The rapid development of CAR T-cell therapies in China is fueled by a mix of domestic innovation and international collaboration. Partnerships with global pharmaceutical companies accelerate clinical trials and regulatory approvals, while Chinese biotech firms are advancing their own proprietary CAR T technologies. This synergy has led to notable breakthroughs, demonstrating the potential and effectiveness of CAR T-cell therapy in treating cancers that are resistant to conventional treatments.
A prime example is Carteyva (relmacabtagene autoleucel), an advanced CD19 CAR-T therapy. Clinical trials have shown impressive results across three types of lymphoma, along with a favorable safety profile, marking a significant milestone in China’s CAR T-cell development.
For international patients, China offers access to these advanced therapies under strict manufacturing and treatment standards, ensuring safety and quality. As of September 2024, six CAR T-cell therapies have received regulatory approval after successful phase I–III trials, highlighting the country’s leadership in the field.
Moreover, China emphasizes patient accessibility by adopting more affordable pricing strategies without compromising quality. For patients with relapsed or refractory cancers, China has emerged as a key destination to receive innovative, effective, and safe CAR T-cell treatments.
China has made significant strides in medical care and research, including advancements in CAR T-cell therapy.
China’s rapid advancements in biotechnologies are establishing it as a leader in CAR T-cell therapy, ensuring effective treatments.
China offers effective CAR T-cell therapies and other medical services with patient-friendly pricing and an accessible approach.
Timely treatment enhances recovery, reduces complications, and improves healthcare efficiency and patient satisfaction.
Hear directly from patient as they share their journey of undergoing CAR-T cell therapy for multiple myeloma in China. From the decision to seek advanced treatment abroad to the experience of care and recovery, this video offers a personal perspective on what patients and families can expect throughout the process.
Send the following reports including medical summary, biopsy, latest blood reports, PET scan report to info@tcellschina.com or Whatsapp us at +86 13578917711.
An expert will go through your reports and provide suggestions for your particular condition. If you wish to talk to the doctor, an online consultation session can be scheduled.
Once you decide to proceed with the treatment, we will arrange a medical visa letter and any other required documents from the hospital. Once your visa is approved, we will assist you with travel preparations and help you with booking your flight tickets.
Our representative will assist in handling all the necessary registration procedures. They will also support you with hospital admission and provide any local assistance you may need. Once your treatment is complete, we will arrange a follow-up consultation with the attending doctor.
CAR-T therapy is an advanced form of immunotherapy where a patient’s own T cells are collected and genetically modified in a laboratory. By inserting a gene that encodes a Chimeric Antigen Receptor (CAR), the T cells are essentially “reprogrammed” to recognize and target specific cancer cells—much like equipping them with a GPS to find and attack tumors, particularly those found in lymphomas and multiple myeloma. This process is referred to as CAR-T cell therapy.
The high cost of CAR-T therapy primarily stems from its personalized nature. It’s not an off-the-shelf drug; rather, it’s tailor-made for each individual patient. The process begins with apheresis to extract T cells from the patient’s blood. These cells are then genetically engineered and expanded in a highly controlled lab environment to create the final CAR-T product. This complex and labor-intensive process takes time, requires specialized facilities, and must be customized for each patient—factors that contribute significantly to its high price.
Studies show that earlier use of CAR-T can significantly improve survival and quality of life. Delaying treatment may mean missing the best chance for effective therapy.
Multiple myeloma is incurable and often relapses after initial success. With each relapse, treatment becomes less effective. After three lines of therapy, the chance of full remission is below 1%, and average survival drops to about 14.5 months.
For patients who don’t respond to multiple treatments, CAR-T may be the only option to extend life. Chinese guidelines now recommend its use after third-line treatment failure.
CAR-T therapy directly attacks tumor cells by damaging their membranes, making it highly effective even for high-risk myeloma. Unlike traditional treatments requiring multiple cycles, CAR-T is a one-time infusion with long-lasting effects—offering patients a simpler and potentially more effective option.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.